Reduced Circulating Soluble Receptor for Advanced Glycation End-products in Chronic Hepatitis B Are Associated with Hepatic Necroinflammation

[1]  A. Alibrandi,et al.  Serum Levels of Soluble Receptor for Advanced Glycation End Products Are Reduced in Euthyroid Children with Newly Diagnosed Hashimoto’s Thyroiditis: A Pilot Study , 2021, Hormone Research in Paediatrics.

[2]  C. Osiowy,et al.  Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management , 2021, Viruses.

[3]  J. Erusalimsky.  The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes , 2021, Redox biology.

[4]  R. Wu,et al.  Assessment of EN-RAGE, sRAGE and EN-RAGE/sRAGE as potential biomarkers in patients with autoimmune hepatitis , 2020, Journal of translational medicine.

[5]  Rashmi Ray,et al.  RAGE and its ligands: from pathogenesis to therapeutics , 2020, Critical reviews in biochemistry and molecular biology.

[6]  A. Alibrandi,et al.  Serum levels of advanced glycation end products (AGEs) are increased and their soluble receptor (sRAGE) reduced in Hashimoto’s thyroiditis , 2020, Journal of Endocrinological Investigation.

[7]  P. Bugert,et al.  Serum levels of advanced glycation end products and their receptors sRAGE and Galectin-3 in chronic pancreatitis. , 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[8]  Huai Wang,et al.  Hepatitis B infection in the general population of China: a systematic review and meta-analysis , 2019, BMC Infectious Diseases.

[9]  O. Shibolet,et al.  Serum Soluble Receptor for AGE (sRAGE) Levels Are Associated With Unhealthy Lifestyle and Nonalcoholic Fatty Liver Disease , 2019, Clinical and translational gastroenterology.

[10]  Hongtao Liu,et al.  Expression of MMP-9 in different degrees of chronic hepatitis B and its correlation with inflammation , 2018, Experimental and therapeutic medicine.

[11]  T. Block,et al.  Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host‐targeting agents to treat chronic hepatitis B , 2018, Antiviral research.

[12]  S. Paul,et al.  RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer—a Review , 2018, Hormones and Cancer.

[13]  L. Foxhall,et al.  Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[14]  M. Lippman,et al.  Targeting RAGE Signaling in Inflammatory Disease. , 2018, Annual review of medicine.

[15]  M. Hollenbach.  The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC) , 2017, International journal of molecular sciences.

[16]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[17]  D. Larrey,et al.  Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance? , 2017, Annals of hepatology.

[18]  Y. Sim,et al.  The diagnostic utility and tendency of the soluble receptor for advanced glycation end products (sRAGE) in exudative pleural effusion. , 2016, Journal of thoracic disease.

[19]  Li Yang,et al.  Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome , 2016, Scientific Reports.

[20]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[21]  A. Enk,et al.  Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma , 2015, International journal of cancer.

[22]  R. Sinha,et al.  Soluble receptor for advanced glycation end products and risk of liver cancer , 2013, Hepatology.

[23]  Y. Jiao,et al.  The Plasma Level of Soluble Receptor for Advanced Glycation End Products is Decreased in Patients with Systemic Lupus Erythematosus , 2012, Scandinavian journal of immunology.

[24]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[25]  J. Upham,et al.  Reduced soluble receptor for advanced glycation end-products in COPD , 2010, European Respiratory Journal.

[26]  Hong Tang,et al.  Histological Changes in Chinese Chronic Hepatitis B Patients with ALT Lower Than Two Times Upper Limits of Normal , 2010, Digestive Diseases and Sciences.

[27]  J. Hoofnagle,et al.  Evaluation of the patient with hepatitis B , 2009, Hepatology.

[28]  E. Kojro,et al.  Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases* , 2008, Journal of Biological Chemistry.

[29]  Benjamin J. Hyatt,et al.  The clinical significance of persistently normal ALT in chronic hepatitis B infection. , 2007, Journal of hepatology.

[30]  A. D'Angelo,et al.  Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[31]  J. Emond,et al.  Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice , 2004, Hepatology.

[32]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[33]  P. Scheuer,et al.  Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.

[34]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .